Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 5/20 | 0.51 |
| ▸ | PRKCA | P17252 | 3/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | BCR | P11274 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8152929 | 0.83 | DUSP10 (0.66) | DUSP10HSP90AA1HSP90AB1PTK2CYP2A6 | |
| SCHEMBL1034731 | 0.82 | DUSP10 (0.54) | DUSP10HSP90AA1HSP90AB1ALDH1A1PRKACA | |
| SCHEMBL13199646 | 0.80 | CCNT1 (0.46) | DUSP10HSP90AA1HSP90AB1PTK2CYP2A6 | |
| SCHEMBL28146832 | 0.79 | LMNA (0.47) | DUSP10ABL1BCRCYP3A4ALDH1A1 | |
| SCHEMBL4272389 | 0.79 | ALDH1A1 (0.58) | DUSP10HSP90AA1HSP90AB1PTK2CYP2A6 | |
| SCHEMBL28286853 | 0.78 | LMNA (0.44) | DUSP10ALDH1A1LMNA | |
| SCHEMBL10817967 | 0.77 | HSP90AA1 (0.64) | DUSP10HSP90AA1HSP90AB1PTK2CYP2A6 | |
| SCHEMBL21526461 | 0.77 | DUSP10 (0.42) | DUSP10HSP90AA1HSP90AB1PTK2CYP2A6 | |
| SCHEMBL21526410 | 0.76 | ACVR1 (0.60) | — | |
| SCHEMBL10917422 | 0.75 | HSP90AA1 (0.60) | DUSP10HSP90AA1HSP90AB1PTK2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | claimed |
| CN-111440147-A | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2020-07-24 | — | — | CN | claimed |
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-111440147-A | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2020-07-24 | — | — | CN | disclosed |
| CN-111440147-A | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2020-07-24 | — | — | CN | disclosed |
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| EP-2007751-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113260-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113260-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | DRD3, DRD2, HTR3A | DUSP10 1895/4885HSP90AA1 2003/4885HSP90AB1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.